| Literature DB >> 28293149 |
Temitayo Aiyelabola1, Ezekiel Akinkunmi2, Isaac Ojo1, Efere Obuotor3, Clement Adebajo4, David Isabirye5.
Abstract
Enantiomerically enriched coordination compounds of aspartic acid and racemic mixtures of coordination compounds of glycine metal-ligand ratio 1 : 3 were synthesized and characterized using infrared and UV-Vis spectrophotometric techniques and magnetic susceptibility measurements. Five of the complexes were resolved using (+)-cis-dichlorobis(ethylenediamine)cobalt(III) chloride, (+)-bis(glycinato)(1,10-phenanthroline)cobalt(III) chloride, and (+)-tris(1,10-phenanthroline)nickel(II) chloride as resolving agents. The antimicrobial and cytotoxic activities of these complexes were then determined. The results obtained indicated that aspartic acid and glycine coordinated in a bidentate fashion. The enantiomeric purity of the compounds was in the range of 22.10-32.10%, with (+)-cis-dichlorobis(ethylenediamine)cobalt(III) complex as the more efficient resolving agent. The resolved complexes exhibited better activity in some cases compared to the parent complexes for both biological activities. It was therefore inferred that although the increase in the lipophilicity of the complexes may assist in the permeability of the complexes through the cell membrane of the pathogens, the enantiomeric purity of the complexes is also of importance in their activity as antimicrobial and cytotoxic agents.Entities:
Year: 2017 PMID: 28293149 PMCID: PMC5331420 DOI: 10.1155/2017/2956145
Source DB: PubMed Journal: Bioinorg Chem Appl Impact factor: 7.778
Figure 1Aspartic acid.
Figure 2Glycine.
Relevant IR bands for the ligands and compounds.
| Compound |
|
|
|
|
|
|---|---|---|---|---|---|
| Aspartic acid | 3380w | 1650s | 1583s | ||
| Glycine | 3119br | 1615s | |||
| Na[Cu(L1)3] | 3380br | 1666br | 1547s | 595br | 682m |
| Na[Cd(L1)3] | 3547,3452br | 1684m | 1512br | 599s | 658s |
| Na[Ni(L1)3] | 3497br | — | 1527w | 595s | 629s |
| Na[Co(L1)3] | 3404w,br | 1654s | 1547s | 598s | 668s |
| Na[Mn(L1)3] | — | 1681s | 1506s | 549s | 601s |
| [Cu(L2)2]2 | 3333br | 1632br | 1416br | 501s | 695s |
| Na[Co(L2)3] | 3428br | 1621s | 1454s | 509s | 672s |
w: weak; m: medium; s: strong; br: broad.
Figure 3trans-Amine/cis-carboxylate isomer (R = –CH2COOH).
Electronic spectra bands for the ligands and complexes.
| Compound | Band I (nm) | Band II (nm) | Band III (nm) | d-d (nm) |
|---|---|---|---|---|
| Aspartic acid | 196 | 212 | 232 | |
| Glycine | 199 | 211 | 244 | |
| Na[Cu(L1)3] | 217 | 223 | 238, 262 | 499, 517 |
| Na[Cd(L1)3] | 217 | 238 | 280, 295 | — |
| Na[Ni(L1)3] | 241 | 310 | 325, 343 | 541, 820 |
| Na[Co(L1)3] | 223 | 241 | 247, 307 | 484, 505 |
| Na[Mn(L1)3] | 217 | 259 | 283, 298 | 550, 574, 679 |
| [Cu(L2)2]2 | — | 265 | — | 620, 632 |
| Na[Co(L2)3] | 220 | 266 | 256 | 520, 667, 682 |
Figure 4The proposed structure for the tris-chelate complexes. R = –H; glycinato complexes; –CH2COOH; aspartato complexes.
Figure 5The proposed structure for the geometric isomers for the tris-chelate complexes. R = –H; glycinato complexes; –CH2COOH; aspartato complexes.
Figure 6The proposed structure for the optical isomer for the tris-chelate complexes. R: –H; glycinato complexes; –CH2COOH; aspartato complexes.
Antimicrobial activities of the compounds.
| Zone of inhibition (size measured included 6.0 mm of the filter paper disc) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Microorganism | Na[Cu(L1)3] | Na[Co(L1)3] | Na[Ni(L1)3] | Na[Co(L2)3] | Na[Cd(L1)3] | Na[Mn(L1)3] | [Cu(L2)2] | Acriflavine | ||||
| P | R | P | R | P | R | P | R | |||||
|
| 6.0 | 6.0 | 6.0 | 6.0 | 6.0 | 8.0 ± 0.9 | 9.0 ± 0.3 | 8.0 ± 0.1 | 6.0 | 6.0 | 6.0 | 20.0 ± 0.4 |
|
| 6.0 | 6.0 | 11.0 ± 0.3 | 8.0 ± 0.2 | 6.0 | 6.0 | 20.2 ± 0.1 | 24.0 ± 0.4 | 6.0 | 8.0 ± 0.5 | 6.0 | 6.0 |
|
| 6.0 | 6.0 | 14.0 ± 0.5 | 6.0 | 6.0 | 6.0 | 9.0 ± 0.2 | 11.0 ± 0.6 | 6.0 | 14.0 ± 0.8 | 6.0 | 15.0 ± 0.6 |
|
| 6.0 | 16.0 ± 0.3 | 6.0 | 12.0 ± 0.2 | 6.0 | 6.0 | 13.0 ± 0.5 | 6.0 | 6.0 | 8.0 ± 0.1 | 6.0 | 20.0 ± 0.2 |
|
| 6.0 | 6.0 | 9.0 ± 0.3 | 18.0 ± 0.8 | 6.0 | 6.0 | 13.1 ± 1,0 | 16.0 ± 0.3 | 6.0 | 8.0 ± 0.6 | 6.0 | 6.0 |
|
| 6.0 | 6.0 | 6.0 | 8.0 ± 0.4 | 6.0 | 8.0 ± 0.5 | 15.0 ± 0.0 | 16.0 ± 0.2 | 6.0 | 20.0 ± 0.4 | 6.0 | 6.0 |
|
| 6.0 | 6.0 | 18 ± 0.2 | 24.0 ± 0.5 | 18.0 ± 0.5 | 9.0 ± 0.1 | 6.0 | 6.0 | 18.0 ± 0.5 | 6.0 | 6.0 | 19.0 ± 0.1 |
L1: aspartic acid; L2: glycine; P: parent compounds of Na[Cu(L1)3], Na[Co(L1)3], Na[Ni(L1)3], Na[Co(L2)3], and Na[Cd(L1)3]; R: parent compounds' respective resolved forms; E. coli: Escherichia coli NCTC 8196; Ps. aeruginosa: Pseudomonas aeruginosa ATCC 19429; P. vulgaris: Proteus vulgaris NCIB; S. aureus: Staphylococcus aureus NCTC 6571; B. subtilis: Bacillus subtilis NCIB 3610; MRSA: methicillin-resistant S. aureus clinical isolate; C. albicans: Candida albicans NCYC 6.
Cytotoxic activity of the parent and resolved compounds.
| Compound | LC50 (95% confidence Interval) (ug/mL) | |
|---|---|---|
| Na[Cu(L1)3] | P | 7.492 (0.003–19.817) |
| R | 4.691 (0.225–10.25) | |
| Na[Co(L1)3] | P | 4.576 (0.001–12.64) |
| R | 4.550 (0.001–12.64) | |
| Na[Ni(L1)3] | P | 4.187 (0.000–13.04) |
| R | 8.044 (0.477–17.49) | |
| Na[Co(L2)3] | P | 7.432 (0.882–14.92) |
| R | 4.775 (−) | |
| L1 | 6.942 (1.007–13.478) | |
| L2 | 13.867 (2.411–28.421) | |
| K2Cr2O7 (Standard) | 3.377 (1.479–4.505) |
Values expressed as L50 values (95% confidence interval).
P: parent compound; R: resolved compound.